ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Kansas City, KS, USA:

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

(BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 1

Novartis
Novartis

Westwood, Kansas, United States and 12 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Westwood, Kansas, United States and 59 other locations

(CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma.The study will consist of 2 parts: dose-escalation ...

Active, not recruiting
Multiple Myeloma
Biological: CC-98633

Phase 1

Juno Therapeutics

Westwood, Kansas, United States and 10 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)

Kansas City, Missouri, United States and 211 other locations

The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...

Enrolling
Multiple Myeloma
Biological: BMS-986393

Phase 2

Juno Therapeutics

Westwood, Kansas, United States and 35 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Kansas City, Kansas, United States and 126 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Elranatamab
Drug: Lenalidomide

Phase 3

Pfizer
Pfizer

Merriam, Kansas, United States and 210 other locations

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 2

Celgene
Celgene

Kansas City, Missouri, United States and 48 other locations

determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...

Enrolling
Multiple Myeloma
Drug: Elranatamab + lenalidomide + dexamethasone
Drug: Elranatamab + Nirogacestat

Phase 2

Pfizer
Pfizer

Kansas City, Kansas, United States and 38 other locations

phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Belantamab mafodotin

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Westwood, Kansas, United States and 40 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems